Overview
- Eli Lilly’s GLP-1 franchise delivered about $1 billion more revenue than Wall Street expected, helping lift shares nearly 4%, according to on-air remarks cited by Insider Monkey.
- Jim Cramer said he initially doubted the market would react to pharma results but called the GLP-1 performance “tech-like” and noted Meta’s weakness may have helped the move.
- Cantor Fitzgerald reaffirmed an Overweight rating and a $925 price target on October 17 despite orforglipron’s exclusion from the first round of Commissioner’s National Priority Vouchers.
- Cantor attributed prior stock pressure to speculation over a potential CNPV for orforglipron, hopes for approval by year-end 2025, and unclear GLP-1 pricing signals tied to Inflation Reduction Act negotiations that could push prices as low as $150 per month.
- Lilly’s oral GLP-1 candidate orforglipron remains a key pipeline focus, with the company planning an obesity filing by the end of 2025 and a type 2 diabetes submission in 2026.